FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University
Fudan University
Gruppo Oncologico del Nord-Ovest
University of California, Davis
Ottawa Hospital Research Institute
Rutgers, The State University of New Jersey
University of Chicago
Maastricht University Medical Center
Maastricht University Medical Center
Assistance Publique Hopitaux De Marseille
Pierre Fabre Medicament
Medical University Innsbruck
Jessa Hospital
Asan Medical Center
Wake Forest University Health Sciences
Maastricht University Medical Center
China Meitan General Hospital
Cantonal Hospital of St. Gallen
Sinphar Pharmaceutical Co., Ltd
Fudan University
Shandong University
Institut de Recherche Clinique sur les Cancers et le Sang
Nanjing Medical University